TRISHA COULBOURN: Open Payments
NPI 1154721231 · EASTON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,761 in 87 payments from 29 companies in 2025. Trend: 2023 $1,110 · 2024 $2,560 · 2025 $1,761
Food & beverage: $1,761
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $237 |
| Novartis Pharmaceuticals Corporation | 14 | $183 |
| Amneal Pharmaceuticals LLC | 8 | $164 |
| Teva Pharmaceuticals USA, Inc. | 6 | $136 |
| PFIZER INC. | 4 | $86 |
| Genentech USA, Inc. | 3 | $66 |
| UCB, Inc. | 3 | $65 |
| Lundbeck LLC | 2 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $65 |
| Axsome Therapeutics, Inc. | 2 | $59 |
Products named: KESIMPTA, CREXONT, QULIPTA, AUSTEDO XR, Ocrevus Zunovo, Rystiggo, VYEPTI, HYQVIA.
Industry payments across MD — which companies pay providers there.
